Last reviewed · How we verify
Extended half-life FVIII concentrates with PK-guided dosing
Extended half-life FVIII concentrates with PK-guided dosing is a Small molecule drug developed by Chulalongkorn University. It is currently FDA-approved.
At a glance
| Generic name | Extended half-life FVIII concentrates with PK-guided dosing |
|---|---|
| Sponsor | Chulalongkorn University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Extended half-life FVIII concentrates with PK-guided dosing CI brief — competitive landscape report
- Extended half-life FVIII concentrates with PK-guided dosing updates RSS · CI watch RSS
- Chulalongkorn University portfolio CI
Frequently asked questions about Extended half-life FVIII concentrates with PK-guided dosing
What is Extended half-life FVIII concentrates with PK-guided dosing?
Extended half-life FVIII concentrates with PK-guided dosing is a Small molecule drug developed by Chulalongkorn University.
Who makes Extended half-life FVIII concentrates with PK-guided dosing?
Extended half-life FVIII concentrates with PK-guided dosing is developed and marketed by Chulalongkorn University (see full Chulalongkorn University pipeline at /company/chulalongkorn-university).
What development phase is Extended half-life FVIII concentrates with PK-guided dosing in?
Extended half-life FVIII concentrates with PK-guided dosing is FDA-approved (marketed).